OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2021
(3)
2026
(2)
2025
(1)
2023
(1)
2022
(1)
2013
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
High-performance anode material for Li-ion batteries from bismuth molybdate incorporating F-free binder.
Not available
S-EPMC12903073
|
biostudies-literature
Cite
Potential inhibitors for SARS-CoV-2 Mpro from marine compounds.
Not available
S-EPMC9034196
|
biostudies-literature
Cite
Imidazole-[1,5‑<i>a</i>]‑Pyridines Can Occupy the EGFR Allostery with a Strong Polar Interaction.
Not available
S-EPMC12917672
|
biostudies-literature
Cite
Computational estimation of potential inhibitors from known drugs against the main protease of SARS-CoV-2.
Not available
S-EPMC9032918
|
biostudies-literature
Cite
Systematic Investigation of the Structure, Stability, and Spin Magnetic Moment of CrM
n
Clusters (M = Cu, Ag, Au, and
n
= 2-20) by DFT Calculations.
Not available
S-EPMC8358970
|
biostudies-literature
Cite
Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial.
Not available
S-EPMC9108376
|
biostudies-literature
Cite
A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients.
Not available
S-EPMC3610419
|
biostudies-literature
Cite
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets